Potassium-competitive acid blocker-based third-line triple therapy in Helicobacter Pylori eradication

Potassium-competitive acid blocker-based third-line triple therapy in Helicobacter Pylori eradication - Potassium-competitive acid blocker-based third-line triple therapy in Helicobacter Pylori eradication

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025252

Enrollment

Registered

2016-12-13

Start date

2015-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic gastritis with H.Pylori infection

Interventions

P-cab 20mg bid + MNZ 250mg bid + STFX 100mg bid x 7days

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 2nd-line eradication failure or penicillin allergy

Exclusion criteria

Exclusion criteria: < 20 years old Patients with severe heart desease, renal dysfunction or liver dysfunction Patients with allergy for 3rd-eradication drugs Patients using anti-coagulation or anti-platelet drugs Pregnants or patient who want pregnancy

Design outcomes

Primary

Measure	Time frame
the antimicrobial susceptibility test and eradication rate after 8weeks	—

Countries

Japan

Contacts

Public ContactHiroshi Mizuta

Kochi medical school Department of gastroenterology and hepatology

mizutahi@kochi-u.ac.jp088-880-2333

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026